Lets face it...your pbth might not work either. IF the deal doesnt go through, then bryan you lose money as pbth will sink like a rock. OPK wouldnt be affected as much by the trade which means that your short position wouldn't be helped. You lose money on both ends.
not surprised.... With OPK dropping it was only a matter of time before the spread would normalize again. Honestly, I sold my shares at 6.35. I wouldn't expect this deal to go through at this price. This was unwanted at $7, so I can only imagine how shareholders feel about it now.
so your argumentation if basically wrapped around insulting peoples characters and appealing to some other authority. So how that makes you a knowledgeable about anything is beyond me. What we know is that you have been posting 5.50 for at the very least 2 months now. Yes the stock has had a pullback, but hell. If the thing went down 5 cents you would spam the board with your "see its going to 5.50" #$%$. You even went as far as to post that the stock would go down to 5.50 if it kept the current trajectory for 5 days. As if the stock was going to drop over 25 percent in a matter of days. Its laughable
bryan, you are an idiot. The article my a@@. You have been short opk for how long? WAY longer than the pbth deal has been on the table. You act as if this has been your plan from the beginning, but in reality, you have lost your shirt in a wrong call and now you wish to quote some basic covered short play. What if the deal goes bad...pbth goes into the $5 range...Then you lose money on both. Who is the goofball. I think you.
it will, but the difference will remain the same until it gets closer to the final date. In other words, the companies will trade together until later.
I really like how you buy a stock to cover your a@@ from your short position with opk, and then proceed to act as if it was your intention all along.
because everyone knows hemophilia is an orphan disease...
To my knowledge, Sangamo isn't focusing on any orphan disease...
honestly, it wouldn't surprise me that they wouldn't release that kind of information. Doesn't mean its a bad thing, but someone somewhere would find a problem and start to question methods and other such things. It would be best to not invite such inquiries until the time that they want to discuss the findings.
That being said, I do think that the company is worth investing in as a long term candidate. What you are investing in with Sangamo isn't just a drug...its the platform (which is great for many reasons). I do think that IF the HIV drug does work (which I hope it does and not just for my wallet's sake) then the stock will certainly sky rocket. I don't believe the company is necessarily overvalued at this point, but I don't think we will see the 10 dollar range for a bit. I think the stock bottomed yesterday at around 7.80 (yeah it was around 7.50 this morning, but ultimately it came back into the green for a nice reversal). I think it will go back to the 8.50 range once confidence gets back up. I wouldn't buy anymore here though. Not a stock issue, but a market issue. I think we are in for a correction at some point and you may be able to get the stock for less.
To tell you the truth...I do not have enough time to do the DD on more stocks. I will look into them, but what makes you think these names are promising? (this isn't an attack, but an actual question)
Im not betting the farm either, but I will say that I am optimistic about the company's platform. Ultimately that's what Im investing in. But to answer your question....It would be nice to see more insider open share buying, but with only having interim data...no matter how great the data is...I couldn't expect much less than what is happening.
Again...you impress me with you argumentation. You are resorting to a red herring to argue your case. Whether or not the insiders buy open market shares is irrelevant to the company's success in their pipeline or platform. Not every insider is as wealthy as Phillip Frost. So what other reason do you have to be bearish on this stock aside from 1) In the past 2 years, there has been insider selling (this point has been dealt with already and is somewhat laughable) and 2) the insiders are not buying open market shares of the stock (which irrelevant to the overall company and great performance shown by the data thus far). Try to stick to the facts instead of diverting to something irrelevant and then bashing the #$%$ out of that.
While i respect your argument, i must say that you are forgetting something. You are comparing apples and oranges. The company 2 years ago is not the company it is today. The time frame of your sell off's doesn't accurately represent what is going on. 2 years ago, there was no active pipeline and the platform was still in development. Now the platform is a success and there is a pipeline.
Again incorrect. The deal is set for 480 million dollars worth of stock. Please read the entire article.
Read the entire thing... It plainly says that the offer is for 480 million for the whole company. The deal is an all stock deal. Divide the 480 million by the number of shares and you get around 7 dollars per share. That is what you get. If opk goes up, you still get seven dollars per share. An example for you: a pizza. You can cut the pizza into however many slices you want...it's still one pizza. That is to say that if I have 1000 shares of pbth then the value is ~$7000. When the deal goes down I get ~7000 dollars worth of opk.